CGON | CG Oncology, Inc. Common stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	23.92 - 26.82
52 Week Range	23.91 - 46.99
Beta	1.43
Implied Volatility	102.73%
IV Rank	28.95%
Day's Volume	1,213,818
Average Volume	635,808
Shares Outstanding	76,829,670
Market Cap	1,881,558,618
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	-1.54
Forward P/E Ratio	N/A
EPS	-15.87
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	61
Country

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

*Chart delayed

Analyzing fundamentals for CGON we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see CGON Fundamentals page.

Watching at CGON technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CGON Technicals page.